Purpose: This paper examines if gender diversity on corporate boards promotes corporate social performance across industries and across countries. Methodology: Fixed-effect panel models are estimated using European-wide data from 2002 through 2013. Instrumental variable estimation and propensity score matching are also employed to control for potential endogeneity. Findings: Board gender diversity improves environmental and social performance, and consequently the corporate social performance. Although the positive effect of gender diversity is prevalent across industries, the effect is more pronounced for firms in emerging markets. Regulatory implications: The findings suggest that gender law that fosters gender diversity can promote corporate social performance in firms and the benefit can be enjoyed with just an introduction of one female director to the board. Promotion of gender diversity in Europe is most beneficial in emerging markets. Originality: The results provide new insights to the literature as we find that a critical mass of female directors on boards is not required to promote corporate social performance. The research also highlights that board gender diversity enhances corporate social performance irrespective of the industry and the effect on corporate social performance is more pronounced in emerging markets where regulations regarding CSR are not so clear-cut.

Available online xxxx JEL classification: G34 J16 M10 M41 a b s t r a c tWe examine the effect board gender diversity has on earnings management in European countries. The findings reveal that a gender diverse board mitigates earnings management in countries where gender equality is high. This provides an explanation to the inconclusive findings in the literature.

No abstract

AimsDevice replacement at the time of battery depletion of implantable cardioverter-defibrillators (ICDs) may carry a considerable risk of complications and engenders costs for healthcare systems. Therefore, ICD device longevity is extremely important both from a clinical and economic standpoint. Cardiac resynchronization therapy defibrillators (CRT-D) battery longevity is shorter than ICDs. We determined the rate of replacements for battery depletion and we identified possible determinants of early depletion in a series of patients who had undergone implantation of CRT-D devices.Methods and resultsWe retrieved data on 1726 consecutive CRT-D systems implanted from January 2008 to March 2010 in nine centres. Five years after a successful CRT-D implantation procedure, 46% of devices were replaced due to battery depletion. The time to device replacement for battery depletion differed considerably among currently available CRT-D systems from different manufacturers, with rates of batteries still in service at 5 years ranging from 52 to 88% (log-rank test, P < 0.001). Left ventricular lead output and unipolar pacing configuration were independent determinants of early depletion [hazard ratio (HR): 1.96; 95% 95% confidence interval (CI): 1.57–2.46; P < 0.001 and HR: 1.58, 95% CI: 1.25–2.01; P < 0.001, respectively]. The implantation of a recent-generation device (HR: 0.57; 95% CI: 0.45–0.72; P < 0.001), the battery chemistry and the CRT-D manufacturer (HR: 0.64; 95% CI: 0.47–0.89; P = 0.008) were additional factors associated with replacement for battery depletion.ConclusionThe device longevity at 5 years was 54%. High left ventricular lead output and unipolar pacing configuration were associated with early battery depletion, while recent-generation CRT-Ds displayed better longevity. Significant differences emerged among currently available CRT-D systems from different manufacturers.

Our study suggests that RV function significantly affects response to CRT. Poor LV reverse remodeling occurs after CRT in patients with HF having severe RV dysfunction at baseline.